Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics
HALO Stock Summary
- Price to trailing twelve month operating cash flow for HALO is currently 116.02, higher than 95.74% of US stocks with positive operating cash flow.
- HALO's price/sales ratio is 24.04; that's higher than the P/S ratio of 91.09% of US stocks.
- Over the past twelve months, HALO has reported earnings growth of -346.9%, putting it ahead of merely 5.12% of US stocks in our set.
- Stocks that are quantitatively similar to HALO, based on their financial statements, market capitalization, and price volatility, are MMX, LITE, QLYS, LSCC, and UTHR.
- Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.
HALO Stock Price Chart Interactive Chart >
HALO Price/Volume Stats
|Current price||$46.56||52-week high||$56.40|
|Prev. close||$47.56||52-week low||$19.36|
|Day high||$49.21||Avg. volume||1,384,887|
|50-day MA||$44.87||Dividend yield||N/A|
|200-day MA||$36.93||Market Cap||6.67B|
Halozyme Therapeutics, Inc. (HALO) Company Bio
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.
HALO Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
Below please find a table outlining a discounted cash flow forecast for HALO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Halozyme Therapeutics Inc ranked in the 4th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Halozyme Therapeutics Inc, consider:
- The compound growth rate in the free cash flow of Halozyme Therapeutics Inc over the past 3.01 years is -0.26%; that's higher than merely 7.7% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately only 19.46% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Halozyme Therapeutics Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 24.6% of US stocks with positive free cash flow.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
HALO Latest News Stream
|Loading, please wait...|
HALO Latest Social Stream
View Full HALO Social Stream
Latest HALO News From Around the Web
Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Artisan Partners Limited Partnership, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2020 investor letter – a copy of which can be downloaded here. A return of 27.07% was recorded by its Investor Class: ARTSX, 27.14% by its Advisor Class: APDSX, and 27.15% by its Institutional Class: APHSX, in the […]
Halozyme Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead….HALO
If you're like many investors, the answer is "yes" -- but if you aren't careful, being fixated on a high P/S ratio can lead you to miss out on some of the best growth stock opportunities. NexoBrid has already been proven safe and effective in phase 3 clinical trials, so it's approaching the final steps before obtaining regulatory approval in the U.S. It's already been authorized in the EU.
HALO Price Returns
Continue Researching HALOWant to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:
Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!